Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies
Efficacy of cancer immunotherapies relies on correct recognition of tumor antigens by lymphocytes, eliciting thus functional responses capable of eliminating tumor cells. Therefore, important efforts have been carried out in antigen identification, with the aim of understanding mechanisms of respons...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2303799 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849717240859983872 |
|---|---|
| author | Belen Aparicio Patrick Theunissen Sandra Hervas-Stubbs Puri Fortes Pablo Sarobe |
| author_facet | Belen Aparicio Patrick Theunissen Sandra Hervas-Stubbs Puri Fortes Pablo Sarobe |
| author_sort | Belen Aparicio |
| collection | DOAJ |
| description | Efficacy of cancer immunotherapies relies on correct recognition of tumor antigens by lymphocytes, eliciting thus functional responses capable of eliminating tumor cells. Therefore, important efforts have been carried out in antigen identification, with the aim of understanding mechanisms of response to immunotherapy and to design safer and more efficient strategies. In addition to classical tumor-associated antigens identified during the last decades, implementation of next-generation sequencing methodologies is enabling the identification of neoantigens (neoAgs) arising from mutations, leading to the development of new neoAg-directed therapies. Moreover, there are numerous non-classical tumor antigens originated from other sources and identified by new methodologies. Here, we review the relevance of neoAgs in different immunotherapies and the results obtained by applying neoAg-based strategies. In addition, the different types of non-classical tumor antigens and the best approaches for their identification are described. This will help to increase the spectrum of targetable molecules useful in cancer immunotherapies. |
| format | Article |
| id | doaj-art-c6814b50000f44d59d15719a8a8fda2c |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-c6814b50000f44d59d15719a8a8fda2c2025-08-20T03:12:43ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2303799Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapiesBelen Aparicio0Patrick Theunissen1Sandra Hervas-Stubbs2Puri Fortes3Pablo Sarobe4Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA) University of Navarra, Pamplona, SpainCancer Center Clinica Universidad de Navarra (CCUN), Pamplona, SpainProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA) University of Navarra, Pamplona, SpainCancer Center Clinica Universidad de Navarra (CCUN), Pamplona, SpainProgram of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA) University of Navarra, Pamplona, SpainEfficacy of cancer immunotherapies relies on correct recognition of tumor antigens by lymphocytes, eliciting thus functional responses capable of eliminating tumor cells. Therefore, important efforts have been carried out in antigen identification, with the aim of understanding mechanisms of response to immunotherapy and to design safer and more efficient strategies. In addition to classical tumor-associated antigens identified during the last decades, implementation of next-generation sequencing methodologies is enabling the identification of neoantigens (neoAgs) arising from mutations, leading to the development of new neoAg-directed therapies. Moreover, there are numerous non-classical tumor antigens originated from other sources and identified by new methodologies. Here, we review the relevance of neoAgs in different immunotherapies and the results obtained by applying neoAg-based strategies. In addition, the different types of non-classical tumor antigens and the best approaches for their identification are described. This will help to increase the spectrum of targetable molecules useful in cancer immunotherapies.https://www.tandfonline.com/doi/10.1080/21645515.2024.2303799Tumor neoantigensmutationsnon-classical tumor antigensribosome profilingimmunopeptidomics |
| spellingShingle | Belen Aparicio Patrick Theunissen Sandra Hervas-Stubbs Puri Fortes Pablo Sarobe Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies Human Vaccines & Immunotherapeutics Tumor neoantigens mutations non-classical tumor antigens ribosome profiling immunopeptidomics |
| title | Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies |
| title_full | Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies |
| title_fullStr | Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies |
| title_full_unstemmed | Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies |
| title_short | Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies |
| title_sort | relevance of mutation derived neoantigens and non classical antigens for anticancer therapies |
| topic | Tumor neoantigens mutations non-classical tumor antigens ribosome profiling immunopeptidomics |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2303799 |
| work_keys_str_mv | AT belenaparicio relevanceofmutationderivedneoantigensandnonclassicalantigensforanticancertherapies AT patricktheunissen relevanceofmutationderivedneoantigensandnonclassicalantigensforanticancertherapies AT sandrahervasstubbs relevanceofmutationderivedneoantigensandnonclassicalantigensforanticancertherapies AT purifortes relevanceofmutationderivedneoantigensandnonclassicalantigensforanticancertherapies AT pablosarobe relevanceofmutationderivedneoantigensandnonclassicalantigensforanticancertherapies |